IL22 and breast carcinoma: Although this previous study did not determine whether IL-22 activated STAT3 in breast cancer cells to reduce their sensitivity to NK cell-meditated cytotoxicity, solid evidences confirm that tumor cell-intrinsic STAT3 activation can impair NK cell antitumor immunity via intricate mechanisms (14).